{"name":"Shaanxi Micot Pharmaceutical Technology Co., Ltd.","slug":"shaanxi-micot-pharmaceutical-technology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MT1013","genericName":"MT1013","slug":"mt1013","indication":"Moderate to severe plaque psoriasis","status":"phase_3"}]}],"pipeline":[{"name":"MT1013","genericName":"MT1013","slug":"mt1013","phase":"phase_3","mechanism":"MT1013 is a small molecule that targets the PDE4 enzyme.","indications":["Moderate to severe plaque psoriasis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQYUlhNXhBeUhFZ3RKM25rYzlYdXBBcnpkZjlaVzBRM2toWi1sWVlIWWxNMjhxTTQxRlVfaU9Xcmd5QjBSMUhPMmdpNERlNTZtTGJEQkl5dzhoSUo1OTRnYjNHX1QtWnlJQXpPTGQ1QkVnZTZ2NmMwblhDcWUzalNmN1AwcTFzV2Qydk10NXBLSFBSWERIeWtydlBxYmtucGhZOFVZ?oc=5","date":"2026-03-31","type":"pipeline","source":"Moomoo","summary":"IPO News | Maiko Aote submits listing application to HKEX for the second time; MT1013 is a globally pioneering dual-target receptor agonist peptide drug. - Moomoo","headline":"IPO News | Maiko Aote submits listing application to HKEX for the second time; MT1013 is a globally pioneering dual-targ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQTHB1SE05UDk0cXN3NWtTdVZMZ0ZBNEIxdXFLZ0hPMXpJTWZpcGtlN1p4VkhqLWJKLUpISEV1SlpBaXR1R2JqbEhZRm0wcXliREJNXzJXM0RsTFN3M25qdy1Hb2VKVmFzbTR0RVV3M0JvTXRYcGpjZGxpeW9FMGhVV3ZQMllRd01TRnNjQ3IzWGJDTlhpS0xHV0FrbWl1MEFqUkppcjl0dTdDUQ?oc=5","date":"2026-03-31","type":"pipeline","source":"富途牛牛","summary":"IPO News | Maikexiaotek Submits Listing Application to HKEX for the Second Time; MT1013 is a Globally First-in-Class Dual-Target Receptor Agonist Peptide Drug - 富途牛牛","headline":"IPO News | Maikexiaotek Submits Listing Application to HKEX for the Second Time; MT1013 is a Globally First-in-Class Dua","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQNTRZQTkwWDNVbFFyNHRTcExMTGdBdC1EbjlwZWFnbFUyTUticFo4MUNvd29VaFJkSHFpQmowNmpNT3F6amdmbFNrVU9Lb2VQQWJoSVFPRVY2MTZnY1RMWjFjMXJWbVczVHN4TXB4Vnp3THQ3MzNfZHhWWWN3V1l3WDBWVTN2Q0t1bTFWWk5yb1h3VW53c2VaUUxVMmtmX0RTc1Y0d3RVMjBaZ1NLNmY1c3M0c0RFYjA?oc=5","date":"2026-02-09","type":"regulatory","source":"thebambooworks.com","summary":"BRIEF: Everest Medicines advances with major licensing deal, new drug application approval - thebambooworks.com","headline":"BRIEF: Everest Medicines advances with major licensing deal, new drug application approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOYjNDYWdCMS1fcDZJaFh3a1VjVFVLZy1OZFAwNFNjdXVqNmRJY21UYjgxSDhRT3E3WjZGd25GMHB3S1JRc1hiX2hMWEhXYnV4T3RIN0IzVndpMjRyLUVVdGtwS2txakhNSEp4ZXdualRhcGQzVjc5NXBrZTZGczlRdXdjdGM3czhuTFQzLXh0Tjh2NmhULWI5NzdkUDhRdnltNzljbkozLS1fN1hJZmc?oc=5","date":"2026-01-08","type":"trial","source":"The Pharma Letter","summary":"Shaanxi Micot raises fresh funds to back lead peptide in Phase II - The Pharma Letter","headline":"Shaanxi Micot raises fresh funds to back lead peptide in Phase II","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPNU5jT3dvUFBZY3hvTEU3UjZpRlBPQm84dF9iMk80SHpFQmY4NTRyX1dkWVN6TFotNUpJQUo3Wnd5RHY3dTZEdl9Fa2dOSE80U3ozY01GblJvbFl3bDltWVJVa09iRHNTRTM3TlRYeHJGdk4wd0doVFc3ZjlfenFsZElESFo0bkpYVHZpVnY3NXpjOHhHYlRuQ3dCamtzQk1YZUJNTGpyN0ZDWk5WcklzNQ?oc=5","date":"2025-10-14","type":"pipeline","source":"The Pharma Letter","summary":"EVerZom raises 10 million euros to push exosome therapy into clinic - The Pharma Letter","headline":"EVerZom raises 10 million euros to push exosome therapy into clinic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQRkptTlFVOWNRYmE1U1huU0JmRk5QUVdUUVF0ZVZvN1VaM2VsRjRodzFkOXdjVXJSakQ3YW96TXQ3UTN5Xzl2RkxFSGN2VHQwcFY2ZUlSSFd1bVUxbjRfSDlLY0ZWNFYwS1cxZ3NMZzE3S0FfbUFqSFNxeC1ycVktZ1o0V01TWWExdGMtZw?oc=5","date":"2025-10-02","type":"pipeline","source":"Yahoo Finance","summary":"Chinese healthcare, biotech firms flock to Hong Kong for IPOs - Yahoo Finance","headline":"Chinese healthcare, biotech firms flock to Hong Kong for IPOs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNOFpuZGpoQnFodmtVejJJcVRqT2MzaGRoYlFaOXo2VmFudGIyRW1scWhWU1o4eDNsemRqWlZrUFJCYlRobVFuaWhjbV9Md281UHQ3Q2hKc0l5MGw4aF9wd2tMU1pKSEF6Vm14MFBGMFMxZXhySVVSMGV3MUZaYUVUU3A1S2VLN1hBMlNVdXlyWVptRTJTN2RwTmdIcWdRVy1Z0gGgAUFVX3lxTE9aWlE4cWlJMXlJMDFMemdpb1NvVy0xLU5SbEEza0ZUMzZJdldXbEZKNUZnNEhESXpyX0J1YmVfdm1UVjk3bWJ0RWlMUThITE9VckNYYXpXT1ppUkJNNDJJMnJIMGtUMmhRcDVyOEl1cHRuTHZfOGN5TVFPb2xJY1FNS1JQRE82ZFM5QzBFRFNMeWJPa3ZFaVAxQmNZZFExSHM?oc=5","date":"2025-10-02","type":"pipeline","source":"South China Morning Post","summary":"Chinese healthcare, biotech firms flock to Hong Kong for IPOs - South China Morning Post","headline":"Chinese healthcare, biotech firms flock to Hong Kong for IPOs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOMUFqZlk0WkVtajB6dlpWSHhTNDlTLTJSVC1lSXRSS0dBWGZBdWlrZWtEYjkwRUFBd0dJbmF3b0JhOXp2MUg3UkluNjJxQlRzWTI1SjNNVkFHbklsZjlUeDB6MmNfSjIxd2lkSllHcThwVHd6cW1LZ1F5MVlEWl94bjVaOTJaSWREdTBtTXRMLVRMbWdOTk1XRkFGZHFOS0xITW5FTV9EZ2x1eWxxVGxZTkgyTGZFUWVqOWpNaFdiS2lCQms?oc=5","date":"2024-10-24","type":"patent","source":"BioWorld News","summary":"Micot (Suzhou) Technology patents new xanthine derivatives for hypertension and asthma - BioWorld News","headline":"Micot (Suzhou) Technology patents new xanthine derivatives for hypertension and asthma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}